J&J, Medivir get EU nod for their hep C drug Olysio

Eric Palmer

The horse race for oral treatments of chronic hepatitis C entered another turn today as the European Union recommended approval of , the Johnson & Johnson and entry in the high-stakes derby, Bloomberg reports.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS